Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27913899 | 0.82 | TSHR (0.38) | TSHRALDH1A1CYP3A4TDP1CYP1A2 | |
| SCHEMBL6371744 | 0.74 | HPRT1 (0.46) | TSHRALDH1A1CYP3A4ACHEHSD17B10 | |
| SCHEMBL2490500 | 0.71 | TDP1 (0.34) | TSHRALDH1A1CYP3A4TDP1ACHE | |
| SCHEMBL15063870 | 0.71 | TSHR (0.50) | TSHRALDH1A1CYP3A4TDP1GPR35 | |
| SCHEMBL5474301 | 0.69 | ALDH1A1 (0.42) | TSHRALDH1A1CYP3A4TDP1ACHE | |
| SCHEMBL2124826 | 0.69 | MAPT (0.49) | ALDH1A1CYP3A4KDM4EHSD17B10CYP1A2 | |
| SCHEMBL4125346 | 0.68 | GPR35 (0.57) | TSHRALDH1A1CYP3A4TDP1GPR35 | |
| SCHEMBL9653333 | 0.68 | TSHR (0.33) | TSHRALDH1A1TDP1HSD17B10CYP1A2 | |
| SCHEMBL455622 | 0.67 | ALDH1A1 (0.48) | TSHRALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL27967204 | 0.66 | HTT (0.39) | ALDH1A1CYP3A4TDP1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936136-B | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111936136-A | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111587114-A | Use of imidazopyrimidines for modulating the immune response in humans | 儿童医学中心公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| CN-103467369-B | The preparation method of nimodipine impurity I | SHANDONG XINHUA PHARMACEUTICAL CO., LTD. (CN) | 2015-11-04 | — | — | CN | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| CN-101823994-A | Antihypertensive compound, synthesis method, application and medicament thereof | UNIV XI AN JIAOTONG | 2010-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | TSHR 2629/4885ALDH1A1 482/4885CYP3A4 26/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | TSHR 2629/4885ALDH1A1 482/4885CYP3A4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.